Creutzfeldt–Jakob disease (CJD) is a rare but devastating neurodegenerative disorder characterized by the pathological misfolding of the cellular prion protein (PrPC) into the pathogenic isoform-scrapie prion protein (PrPSc), ultimately leading to fatal outcomes. Cerebrospinal fluid (CSF) biomarkers play a pivotal role in early diagnosis, longitudinal monitoring, and prognostic assessment, thereby enhancing the clinical management of this challenging disease. This review summarizes the established CSF biomarkers, 14-3-3 protein, tau protein (total tau), phosphorylated tau isoforms, α-synuclein, neurofilament light chain (Nfl), S100B, neuron-specific enolase (NSE), and phosphorylated neurofilament heavy chain (pNFH), highlighting typical sensitivity ranges (14-3-3 ~70–85%; RT-QuIC > 90%) and subtype-dependent performance variation. We further dissect limitations related to assay variability, inter-laboratory cut-off inconsistencies, and reduced specificity in non-prion dementias. Looking ahead, we discuss emerging multi-omics discovery, integration of CSF with blood-based biomarkers and imaging signatures, and AI-enabled diagnostic modeling. We propose a three-tier biomarker framework combining Real-Time Quaking-Induced Conversion (RT-QuIC) as a confirmatory assay, tau/NfL/pNFH as injury-severity indicators, and multi-omics-derived signatures for early detection and prognosis stratification.
Prion diseases are fatal neurodegenerative disorders characterized by profound neuronal damage. Despite evidence supporting a neuroprotective role for β-synuclein (β-syn) in neurodegeneration, its potential functions and mechanisms in prion disease have not been elucidated. To investigate the role of β-syn, we systematically analyzed its alterations in the central nervous system of several prion-infected rodent models and cell models. A series of biochemical, cellular, and immunofluorescence assays were conducted to explore the relationship between β-syn and protein kinase B (Akt) signaling and between β-syn and prion protein (PrP), and its neuroprotective role in prion disease. Student’s t-test was used for statistics. At the terminal stage of prion disease, β-syn and Akt exhibited a parallel and remarkable decrease in rodent brains, contrasting with the slight but significant increase observed at early to middle stages. Dual-stained immunofluorescence assays confirmed that β-syn is localized within NeuN-positive neurons. Further structural and functional analyses revealed a high-affinity molecular interaction between β-syn and Akt, with the N-terminal region of β-syn being essential for binding to Akt1. In a cell model of PrP aggregation, β-syn overexpression suppressed cytochrome c-induced apoptosis, which was demonstrated by decreased levels of cleaved caspase-3. Notably, this anti-apoptotic effect was partially abolished upon Akt knockdown, indicating a dependence on Akt signaling. Moreover, colocalization of β-syn and PrP was observed in rodent brains. Consistently, in cellular models of prion infection and PrP aggregation, β-syn overexpression not only reduced PrP levels but also ameliorated its aberrant histological distribution. Our findings demonstrate that the anti-apoptotic activity of β-syn, mediated via Akt signaling, is severely lost during prion infection, thereby suggesting a mechanism of intrinsic neuronal vulnerability and revealing a novel therapeutic strategy.
Prion diseases (PrDs) are fatal neurodegenerative disorders characterized by the accumulation of misfolded prion protein (PrPSc) and progressive impairment of protein quality-control systems. Lysosomal dysfunction and defective autophagic flux contribute to PrPSc accumulation, but the upstream regulatory mechanisms remain incompletely defined. In this study, we investigated the regulatory role of miR-148a-3p during prion infection. We found that miR-148a-3p expression is markedly increased in ME7- and 139A-infected mouse brains and prion-infected SMB-S15 cells. Dual-luciferase assays confirmed that miR-148a-3p directly targets the PRNP 3′UTR, negatively regulating cellular PrP expression. In prion-infected cells, inhibition of miR-148a-3p reduced proteinase K (PK)-resistant PrP (PrPres), delayed RT-QuIC conversion, and decreased PMCA-amplified PrPres. Through bioinformatic prediction and experimental validation, we identified ATP6AP2, a V-ATPase-associated regulator of lysosomal acidification, as a high-confidence target of miR-148a-3p. ATP6AP2 expression was significantly decreased in sCJD transcriptomic data, scrapie-infected mouse brains, and prion-infected cells. Importantly, inhibition of miR-148a-3p restored ATP6AP2 expression, which improved lysosomal acidification and alleviated impaired autophagic flux. Furthermore, overexpression of ATP6AP2 directly reduced PrPSc accumulation in SMB-S15 cells and diminished prion seeding capacities in RT-QuIC and PMCA assays. These findings identify miR-148a-3p as an upstream regulator of ATP6AP2-dependent lysosomal dysfunction in prion infection. Inhibition of miR-148a-3p may restore lysosomal clearance capacity and reduce PrPSc accumulation, suggesting a potential regulatory strategy for PrDs.